RADCQ — Rite Aid Share Price
Last trade - 00:00- $0.57m
- $3.69bn
- $24.09bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -235.91% | ||
| Return on Equity | n/a | ||
| Operating Margin | -6.11% | ||
Financial Summary
| Year End 4th Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 21,639.56 | 21,928.39 | 24,043.24 | 24,568.26 | 24,091.9 | 22,915.2 | 23,155 | 2.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rite Aid Corporation is a full-service pharmacy engaged in improving health outcomes. The Company meets customer needs with a range of solutions that offer convenience, including retail and delivery pharmacy, as well as services offered through its wholly owned subsidiaries Health Dialog Services Corporation (Health Dialog) and Bartell Drug Company (Bartell Drugs). Health Dialog provides healthcare coaching and disease management services via live online and phone health services. Regional chain Bartell Drugs supports the health and wellness needs in the Seattle area. Its Retail Pharmacy segment’s primary business is the sale of prescription drugs and related consultation to its customers. Additionally, the Retail Pharmacy segment sells a full selection of health and beauty aids and personal care products, seasonal merchandise, and a large private brand product line. The Company operates more than 1,700 retail pharmacy locations across 16 states.
Directors
- Bruce Bodaken NEC (69)
- Heyward Donigan PRE (60)
- Matthew Schroeder CFO (51)
- Lance Neill COO
- Jessica Kazmaier CHO (44)
- Justin Mennen EVP (40)
- Paul Gilbert EVP (50)
- Jocelyn Konrad EVP (51)
- Erik Keptner SVP (48)
- Brian Hoover CAO (56)
- Andre Persaud OTH (52)
- Elizabeth Burr IND (59)
- Bari Harlam IND (60)
- Robert Knowling IND (66)
- Kevin Lofton IND (66)
- Louis Miramontes IND (66)
- Arun Nayar IND (70)
- Katherine Quinn IND (56)
- Last Annual
- March 4th, 2023
- Last Interim
- September 2nd, 2023
- Incorporated
- April 15th, 1968
- Public Since
- May 22nd, 1981
- No. of Shareholders
- 9,823
- No. of Employees
- 47,000
- Sector
- Food & Drug Retailing
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 56,542,469
- Address
- 1200 INTREPID AVENUE, 2ND FLOOR, PHILADELPHIA, 19112
- Web
- https://www.riteaid.com/
- Phone
- +1 7177612633
- Contact
- Byron Purcell
- Auditors
- Deloitte & Touche LLP
Upcoming Events for RADCQ
Similar to RADCQ
American Green
Pink Sheets on Nasdaq
Bit Brother
Pink Sheets on Nasdaq
Blue Gem Enterprise
Pink Sheets on Nasdaq
Blum Holdings
Pink Sheets on Nasdaq
Can B
Pink Sheets on Nasdaq
FAQ
As of Today at 22:58 UTC, shares in Rite Aid are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Rite Aid last closed at $0.00 and the price had moved by -99.95% over the past 365 days. In terms of relative price strength the Rite Aid share price has underperformed the S&P500 Index by -99.96% over the past year.
The overall consensus recommendation for Rite Aid is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Rite Aid does not currently pay a dividend.
Rite Aid does not currently pay a dividend.
Rite Aid does not currently pay a dividend.
To buy shares in Rite Aid you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Rite Aid had a market capitalisation of $0.06m.
Here are the trading details for Rite Aid:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RADCQ
Based on an overall assessment of its quality, value and momentum Rite Aid is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Rite Aid is $1.00. That is 99900% above the last closing price of $0.00.
Analysts covering Rite Aid currently have a consensus Earnings Per Share (EPS) forecast of -$4.83 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rite Aid. Over the past six months, its share price has underperformed the S&P500 Index by -99.45%.
As of the last closing price of $0.00, shares in Rite Aid were trading -99.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rite Aid PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rite Aid's management team is headed by:
- Bruce Bodaken - NEC
- Heyward Donigan - PRE
- Matthew Schroeder - CFO
- Lance Neill - COO
- Jessica Kazmaier - CHO
- Justin Mennen - EVP
- Paul Gilbert - EVP
- Jocelyn Konrad - EVP
- Erik Keptner - SVP
- Brian Hoover - CAO
- Andre Persaud - OTH
- Elizabeth Burr - IND
- Bari Harlam - IND
- Robert Knowling - IND
- Kevin Lofton - IND
- Louis Miramontes - IND
- Arun Nayar - IND
- Katherine Quinn - IND